Armata Pharmaceuticals (ARMP) Change in Accured Expenses (2013 - 2026)

Armata Pharmaceuticals has reported Change in Accured Expenses for 14 years, with the latest figure at -$352000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 36.35% year-over-year to -$352000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112000.0 (up 103.97% YoY) and the FY2025 annual result came in at -$89000.0, up 97.63% from the prior year.
• Change in Accured Expenses fell to -$352000.0 in Q1 2026 per ARMP's latest filing, from $348000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.5 million in Q2 2023 and troughed at -$1.7 million in Q4 2024.
• A 5-year average of -$262529.4 and a median of -$265000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 331.06% in 2022, then tumbled 4330.43% in 2023.
• Over 5 years, Change in Accured Expenses stood at $23000.0 in 2022, then sank by 4330.43% to -$973000.0 in 2023, then tumbled by 77.18% to -$1.7 million in 2024, then jumped by 120.19% to $348000.0 in 2025, then tumbled by 201.15% to -$352000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$352000.0, $348000.0, and $381000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.